Effectiveness and safety of eribulin for human epidermal growth factor receptor 2 negative metastatic breast cancer in a real-world population.
Rocío Díaz AcedoSilvia Artacho CriadoRocío Jiménez GalánAntonio Gutiérrez PizarrayaMercedes Galván BanqueriMaría Rodríguez-de-la-Borbolla-ArtachoJosé Antonio Marcos RodríguezEsther Márquez SaavedraPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021)
Effectiveness of eribulin in a real-life human epidermal growth factor receptor-2--negative population is lower than that observed in clinical trials. Its benefit seems to be higher in patients with hormonal receptor expression and patients who had received capecitabine prior to eribulin. The safety profile of eribulin is adequate.
Keyphrases
- metastatic breast cancer
- epidermal growth factor receptor
- tyrosine kinase
- advanced non small cell lung cancer
- endothelial cells
- clinical trial
- induced pluripotent stem cells
- randomized controlled trial
- systematic review
- type diabetes
- polycystic ovary syndrome
- insulin resistance
- study protocol
- adipose tissue
- open label